Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EDIT logo EDIT
Upturn stock ratingUpturn stock rating
EDIT logo

Editas Medicine Inc (EDIT)

Upturn stock ratingUpturn stock rating
$2.69
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/12/2025: EDIT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

15 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4 Target price
52w Low $0.91
Current$2.69
52w High $4.12

Analysis of Past Performance

Type Stock
Historic Profit -5.29%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 241.89M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 15
Beta 2.16
52 Weeks Range 0.91 - 4.12
Updated Date 09/13/2025
52 Weeks Range 0.91 - 4.12
Updated Date 09/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.84

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -711.63%

Management Effectiveness

Return on Assets (TTM) -33.76%
Return on Equity (TTM) -188.58%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 84519241
Price to Sales(TTM) 6.22
Enterprise Value 84519241
Price to Sales(TTM) 6.22
Enterprise Value to Revenue 2.17
Enterprise Value to EBITDA -1.36
Shares Outstanding 89920200
Shares Floating 89572173
Shares Outstanding 89920200
Shares Floating 89572173
Percent Insiders 0.3
Percent Institutions 49.2

ai summary icon Upturn AI SWOT

Editas Medicine Inc

stock logo

Company Overview

overview logo History and Background

Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. It's a clinical-stage genome editing company focused on developing transformative genomic medicines for a broad range of serious diseases. It has gone through preclinical and clinical stages with milestones achieved in its EDIT-101 program.

business area logo Core Business Areas

  • Therapeutic Development: Focuses on developing and commercializing CRISPR-based genome editing therapeutics across various disease areas including ocular, oncology, and other genetic diseases.
  • Technology Platform: Advancing their CRISPR technology platform, including novel CRISPR enzymes and delivery methods, to improve the safety and efficacy of gene editing.
  • Research and Development: Conducting research and development activities to discover new targets and develop innovative gene editing therapies.

leadership logo Leadership and Structure

The leadership team consists of key executives responsible for research, clinical development, and corporate strategy. The organizational structure involves research, development, clinical, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • EDIT-101: An experimental AAV5-delivered CRISPR medicine being developed for the treatment of Leber congenital amaurosis 10 (LCA10), a form of inherited blindness. Currently in clinical trials (Phase 1/2). Competitors include companies developing gene therapies for inherited retinal diseases. Revenue is currently limited to partnership/licensing agreements until EDIT-101 is approved. Market share is currently 0 as it's not approved for sale yet.
  • EDIT-301: An experimental gene editing medicine in Phase 1/2 trials for severe sickle cell disease. EDIT-301 utilizes Editas' proprietary AsCas12a enzyme. Competitors include Vertex Pharmaceuticals (CRSP) and Bluebird Bio (BLUE) with their approved and experimental gene therapies for sickle cell disease. Market share is currently 0 as it's not approved for sale yet.

Market Dynamics

industry overview logo Industry Overview

The gene editing industry is rapidly evolving, driven by technological advancements and increasing applications in healthcare. It is characterized by high R&D investments, regulatory scrutiny, and intense competition.

Positioning

Editas Medicine is positioned as a leading player in the CRISPR gene editing space, focusing on developing therapies for inherited diseases. Its competitive advantage lies in its proprietary CRISPR technology and clinical programs.

Total Addressable Market (TAM)

The TAM for gene editing therapies is estimated to reach billions of dollars annually. Editas is positioned to capture a significant share with successful clinical trials and commercialization.

Upturn SWOT Analysis

Strengths

  • Pioneering CRISPR technology platform
  • Strong intellectual property portfolio
  • Experienced leadership team
  • Clinical-stage programs with promising results
  • Strategic partnerships with leading institutions

Weaknesses

  • High cash burn rate
  • Dependence on clinical trial success
  • Regulatory uncertainties
  • Limited commercial infrastructure
  • Relatively small market capitalization compared to competitors

Opportunities

  • Expanding therapeutic applications of CRISPR
  • Partnering with pharmaceutical companies for co-development
  • Advancements in gene delivery technologies
  • Receiving regulatory approvals for lead candidates
  • Addressing unmet medical needs in genetic diseases

Threats

  • Competition from other gene editing companies
  • Adverse clinical trial outcomes
  • Regulatory delays or rejection
  • Ethical concerns surrounding gene editing
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • CRSP
  • BEAM
  • NTLA
  • BLUE

Competitive Landscape

Editas Medicine is a key player in the gene editing field but faces stiff competition from larger and more established companies. They have a strong technology platform but must demonstrate clinical success to gain market share.

Growth Trajectory and Initiatives

Historical Growth: Historical growth depends on the specific period being considered. Financial records should be consulted for accuracy.

Future Projections: Future projections depend on analyst estimates and market conditions. These can be obtained from financial news providers.

Recent Initiatives: Recent initiatives include advancing clinical trials of EDIT-101 and EDIT-301 and expanding partnerships.

Summary

Editas Medicine is a pioneering CRISPR gene editing company with promising clinical programs, particularly EDIT-101 and EDIT-301. Their strength lies in their innovative technology, but they face challenges related to funding, clinical trial outcomes, and competition. The company needs to successfully navigate the regulatory landscape and achieve clinical milestones to capitalize on the growing gene editing market. Managing cash burn and securing additional funding will also be important for future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC), Analyst reports, Press releases

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share percentages are approximations.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Editas Medicine Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2016-02-03
President, CEO & Director Dr. Gilmore O'Neill M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 246
Full time employees 246

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.